Digoxin

Overview

Digoxin (Lanoxin®) is a cardiac glycoside used in veterinary medicine primarily as an antiarrhythmic agent in dogs and cats. It is most commonly indicated for control of ventricular rate in supraventricular tachyarrhythmias, particularly atrial fibrillation, and is frequently used in patients with concurrent heart failure.

Digoxin has a relatively narrow therapeutic index, and its clinical use requires careful dose titration and monitoring of serum drug concentrations. Oral bioavailability varies depending on formulation, and steady-state levels are typically assessed after 7–10 days of therapy using trough serum measurements.

Mechanism of Action (MOA): Digoxin inhibits the Na⁺–K⁺ ATPase pump, leading to increased intracellular sodium, which is exchanged for calcium, resulting in increased intracellular calcium and a positive inotropic effect. In addition, it exerts a vagomimetic effect on the atrioventricular (AV) node, slowing AV nodal conduction and reducing ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

Indications

Digoxin is primarily used in dogs and cats for the management of supraventricular tachyarrhythmias, particularly when control of ventricular rate is required. Its use is most appropriate in stable patients with cardiac disease, especially those with concurrent heart failure.

• Atrial fibrillation (rate control): First-line or adjunctive therapy to reduce ventricular rate in dogs with atrial fibrillation, improving cardiac efficiency and clinical signs.
• Combination therapy with diltiazem: Frequently combined with diltiazem for more effective ventricular rate control when monotherapy is insufficient.
• Other supraventricular tachyarrhythmias: May be used in selected cases to slow AV nodal conduction and control heart rate.
• Heart failure with atrial fibrillation: Improves cardiac output through combined rate control and mild positive inotropic effects.

Dosage (Reference)

Dog

In dogs, digoxin dosing must be carefully individualized due to its narrow therapeutic index. Doses are calculated based on lean body weight, and therapy should be initiated at the lower end of the dose range, followed by gradual adjustment based on clinical response and serum drug concentrations.

Cat

In cats, digoxin must be used with increased caution due to higher sensitivity to toxicity. Lower doses and extended dosing intervals are typically required, with careful monitoring of clinical response and serum drug levels.

Warnings & Precautions

Digoxin has a narrow therapeutic index, and small changes in dose, patient condition, or concurrent medications can significantly affect its safety and efficacy. Careful patient selection, dose adjustment, and monitoring are essential in both dogs and cats.

• Narrow therapeutic index: Small differences between therapeutic and toxic doses; requires careful dose calculation and routine monitoring of serum drug levels.
• Renal dysfunction: Primarily eliminated by the kidneys; reduced clearance in renal disease increases risk of accumulation and toxicity—dose reduction or extended dosing intervals are required.
• Electrolyte imbalances: Hypokalaemia significantly increases the risk of toxicity; electrolyte abnormalities should be corrected before and during therapy.
• Cardiac conduction disorders: Contraindicated in patients with atrioventricular (AV) block or frequent ventricular arrhythmias due to risk of worsening conduction disturbances.
• Feline sensitivity: Cats are more sensitive to toxic effects; use lower doses and monitor closely for early signs of toxicity.
• Hypertrophic cardiomyopathy (cats): Generally avoided in cats with hypertrophic cardiomyopathy due to potential for adverse effects.
• Geriatric and obese patients: Altered pharmacokinetics may increase risk of toxicity; dosing should be based on lean body weight and adjusted carefully.
• Intravenous administration: Rarely indicated; if used, must be administered very slowly with extreme caution due to risk of adverse cardiovascular effects.
• Monitoring requirements: Serum digoxin levels should be measured after steady state is reached (7–10 days), with samples collected 6–8 hours post-dose to guide safe dose adjustments.

Drug Interactions

Digoxin has numerous clinically important drug interactions that may alter its absorption, serum concentration, or toxicity risk. Most interactions result in either reduced therapeutic effect or increased risk of digoxin toxicity, requiring dose adjustment and close monitoring.

• Reduced GI absorption: Antacids, cimetidine, and metoclopramide may decrease digoxin absorption, reducing its clinical effectiveness.
• Chemotherapy agents: Drugs such as cyclophosphamide, cytarabine, doxorubicin, and vincristine may reduce gastrointestinal absorption of digoxin.
• Amiodarone: Increases serum digoxin levels and risk of toxicity; dose reduction of digoxin is often required.
• Verapamil: Decreases digoxin clearance, increasing serum concentration and toxicity risk.
• Erythromycin and oxytetracycline: May increase serum digoxin levels, likely by altering intestinal flora and drug metabolism.
• Loop and thiazide diuretics: Increase risk of toxicity indirectly by causing hypokalaemia, which enhances digoxin effects.
• Antimuscarinics and diazepam: May enhance the pharmacologic or toxic effects of digoxin.
• Spironolactone: May either increase or decrease digoxin toxicity; effects are variable and require monitoring.

Side Effects & Overdose

Side Effects

Adverse effects of digoxin are relatively common due to its narrow therapeutic index and are often dose-related. Cats are generally more sensitive to toxic effects than dogs, and early recognition of clinical signs is critical.

• Gastrointestinal signs: Anorexia, vomiting, and diarrhoea are often the earliest indicators of toxicity.
• CNS effects: Depression and lethargy may occur, particularly with elevated serum concentrations.
• Cardiac arrhythmias: Can induce or worsen arrhythmias, including AV block, bigeminy, and paroxysmal tachyarrhythmias.
• Increased sensitivity in cats: Toxic effects occur more readily and at lower doses compared to dogs.
• Electrolyte-related toxicity: Hypokalaemia significantly increases the likelihood and severity of adverse effects.

Overdose

Digoxin overdose can result in serious and potentially life-threatening complications, particularly affecting the cardiovascular and gastrointestinal systems. Toxicity may occur with acute overdose or gradual accumulation.

• Severe arrhythmias: Life-threatening conduction disturbances including AV block and ventricular arrhythmias.
• Marked gastrointestinal signs: Persistent vomiting, diarrhoea, and anorexia.
• CNS depression: Weakness, depression, and reduced responsiveness.
• Predisposing factors: Renal dysfunction and hypokalaemia increase the risk of accumulation and toxicity.
• Management: Discontinue digoxin and provide supportive care, including correction of electrolyte imbalances and monitoring of cardiac rhythm.
• Antiarrhythmic therapy: Lidocaine or phenytoin may be used to control digoxin-induced arrhythmias.

Key Notes

Practical clinical points that help optimize the safe and effective use of digoxin in dogs and cats in everyday veterinary practice:

• Delayed steady state: Full therapeutic effect is not immediate; allow adequate time (about 7–10 days) before making dose adjustments.
• Formulation variability: Oral bioavailability differs between tablets and elixir, which may influence dosing consistency when switching formulations.
• Combination therapy benefit: More effective ventricular rate control is often achieved when combined with diltiazem rather than using digoxin alone.
• Clinical response over dose: Treatment success should be guided by heart rate control and clinical improvement rather than relying solely on dose calculations.
• Lean body weight dosing: Especially important in overweight animals to avoid inadvertent overdosing.
• Limited role of IV use: Parenteral administration is rarely required in clinical practice and should not be considered routine therapy.
• Chronic therapy drug: Typically used as long-term management rather than short-term intervention for arrhythmias.